Cost-Effectiveness Analysis of Xpert MTB/RIF for Multi-Outcomes of Patients With Presumptive Pulmonary Tuberculosis in Thailand-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Xpert MTB/RIF for Multi-Outcomes of Patients With Presumptive Pulmonary Tuberculosis in Thailand

Published:2020-05 Issue: Volume:21 Page:264-271
ISSN:2212-1099
Container-title:Value in Health Regional Issues
language:en
Short-container-title:Value in Health Regional Issues

Author:

Khumsri Jiraporn,Hanvoravongchai Piya,Hiransuthikul Narin,Chuchottaworn Charoen

Funder

National Research Council of Thailand

90th Anniversary of Chulalongkorn University Ratchadaphiseksomphot

Publisher

Elsevier BV

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)

Reference19 articles.

1. Cross-sectional studies of tuberculosis prevalence in Cambodia between 2002 and 2011;Mao;Bull World Health Organ,2014

2. Smear-positive pulmonary tuberculosis and AFB examination practices according to the standard checklist of WHO’s tuberculosis laboratory assessment tool in three governmental hospitals, Eastern Ethiopia;Mekonnen;BMC Res Notes,2014

3. Comparing same day sputum microscopy with conventional sputum microscopy for the diagnosis of tuberculosis–Chhattisgarh, India;Priyakanta;PLoS ONE,2013

4. Toman’s Tuberculosis Case Detection, Treatment, and Monitoring,2004

5. Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States;Choi;Int J Tuberc Lung Dis,2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Application Value of Sat-Tb Combined with Roche Solid Culture in the Diagnosis and Treatment of Tuberculosis;2024

2. Detection and factors associated with tuberculosis and rifampicin resistance among presumptive patients at the Thailand-Myanmar border;Tropical Biomedicine;2022-11-30

3. Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand;ClinicoEconomics and Outcomes Research;2022-02